Endpoint surrogacy in oncology Phase 3 randomised controlled trials.

Journal Article (Editorial)

Endpoint surrogacy is an important concept in oncology trials. Using a surrogate endpoint like progression-free survival as the primary endpoint-instead of overall survival-would lead to a potential faster drug approval and therefore more cancer patients with an earlier opportunity to receive the newly approved drugs.

Full Text

Duke Authors

Cited Authors

  • Zhang, J; Pilar, MR; Wang, X; Liu, J; Pang, H; Brownson, RC; Colditz, GA; Liang, W; He, J

Published Date

  • August 2020

Published In

Volume / Issue

  • 123 / 3

Start / End Page

  • 333 - 334

PubMed ID

  • 32451466

Pubmed Central ID

  • PMC7403397

Electronic International Standard Serial Number (EISSN)

  • 1532-1827

Digital Object Identifier (DOI)

  • 10.1038/s41416-020-0896-5


  • eng

Conference Location

  • England